RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication
Artículo científico (JournalArticle)
Association of miR-126-3p, miR-1260b and miR-374a-5p with the incidence of heart failure in a population-based cohort: the Hortega Follow-Up Study
[EN] Background: Circulating microRNAs (miRNAs) are emerging markers for cardiovascular prevention and control. miRNAs associated to vascular damage are candidates to play a causal role in the microvascular dysfunction of heart failure (HF). The aim was to evaluate the observational and causal (Mendelian randomization) association of miRNAs related with vascular alterations (miR-126-3p, miR-1260b and miR-374a-5p) with HF incidence in a sample from the general population. Methods: Plasma miRNAs levels were measured in 985 Hortega Study participants using real time quantitative polymerase chain reaction (RT-qPCR). Single nucleotide polymorphisms (SNPs) were genotyped with the TOPMED imputable Illumina GSA array. We identified genetic instrumental variables for miR-126-3p (33 SNPs), miR-1260b (22 SNPs) and miR-374a-5p (35 SNPs) and run several Mendelian randomization approaches. Results: The hazard ratio (95 % confidence interval) of HF by a 10-fold increase in miR-126-3p, miR-1260b and miR-374a-5p was 1.53 (1.09, 2.14), 1.38 (1.03, 1.86), and1.30 (1.09, 1.57), respectively. The corresponding rate differences were 9.7 (-0.1, 19.5), 12.0 (0.4, 23.6) and 9.1 (1.2, 17.1) per 10000 person-years. In flexible dose-response analysis, increased miRNAs levels were associated with higher HF risk, both in the relative and additive scale. In Mendelian randomization analysis, consistently suggestive positive causal associations were found with HF for increased miR-126-3p and miR-1260b levels, but not for miR-374a-5p. Conclusions: In observational analysis, miR-126-3p, miR-1260b and miR-374a-5p levels were positively associ-ated with HF incidence. Mendelian randomization analysis supported a causal role for miR-126-3p and miR-1260b, thus suggesting a potential use as prognostic and therapeutic targets for HF prevention and control., We thank Nuria Alvarez y Belen Herraez, from the Human Genotyping-CEGEN Unit, at the National Center for Cancer Research from the Carlos III Health Institutes, in Madrid (Spain) , for their contribution in the genotyping procedure. This research was funded by health sciences research grants from the Carlos III Health Institute (grant numbers PI19/01796 to J.R.; PI21/00249 and CP22/00069 to R.C.; PI23/01179 to A.O.; FI20/00096 to O.M.-A; and FI22/00032 to A.F.-C.; PI15/00071 and PI22CIII/00029 to M.T.-P.) . This work was also sup-ported by the State Agency for Research (PID2019-108973RB-C21 to M. T.-P.) . Grant IJC2020-045308-I, Juan de la Cierva Incorporacion funded by MCIN/AEI/10.13039/501100011033 and by ESF-Investing in Your Future (to A.O.) ; CNS2022-136175, Research Consolidation Grants, funded by MCIN/AEI/10.13039/501100011033 and European Union "Next Generation EU"/PRTR" (to R.C) .; FP7-HEALTH 11 (grant number no 278249) . It was co-funded by the European Union (the European Regional Development Fund (ERDF) and the European Social Fund (FSE) ) ; CIBER of Obesity and Nutrition Physiopathology (CIBEROBN) (grant numbers CIBER-02-08-2009, CB06/03 and CB12/03/30016) . CIBER of Cardiovascular diseases (CIBERCV) (grant number CB16/11/00261) . CIBEROBN and CIBERCV are co-funded with European Funds for Regional Development (FEDER) , and IDIFEDER/2021/072, CIAICO/2022/181 and INVEST/2023/180 from the Generalitat Valenciana of Spain. Z.R.-H. received a fellowship associated to a Spain National Investigation Agency project (PRE2020-093926) . The genotyping service was carried out at the Genotyping Unit-CEGEN in the Spanish Na-tional Cancer Research Centre (CNIO) , supported by Instituto de Salud Carlos III (ISCIII) , Ministerio de Ciencia e Innovacion. CEGEN is part of the initiative IMPaCT GEN oMICA (IMP/00009) cofunded by ISCIII and the European Regional Development Fund (ERDF)
Project:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-108973RB-C21
,
European Commission / FP7 278249
,
Generalitat Valenciana IDIFEDER/2021/072
,
Generalitat Valenciana CIAICO/2022/181
,
Generalitat Valenciana INVEST/2023/180
,
Instituto de Salud Carlos III PI19/01796
,
Instituto de Salud Carlos III CP22/00069
,
Instituto de Salud Carlos III PI23/01179
,
Instituto de Salud Carlos III FI20/00096
,
Instituto de Salud Carlos III FI22/00032
,
Instituto de Salud Carlos III PI22CIII/00029
,
Instituto de Salud Carlos III PI21/00249
,
Instituto de Salud Carlos III PI15/00071
,
Instituto de Salud Carlos III CB06/03/0052
,
Centro de Investigación Biomédica en Red CB12/03/30016
,
Centro de Investigación Biomédica en Red CIBER-02-08-2009
,
Agencia Estatal de Investigación PRE2020 093926
,
Ministerio de Ciencia e Innovación CNS2022-136175
,
Ministerio de Ciencia e Innovación IJC2020-045308-I